ATE250063T1 - Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen - Google Patents

Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen

Info

Publication number: ATE250063T1
Authority: AT; Austria
Prior art keywords: treatment; pyrazolopyrimidinone; cgmp pde5; pde5 inhibitors; sexual disorders
Prior art date: 1998-10-23

Application number

AT99970992T

Other languages

English (en)

Inventor

Mark Edward Bunnage

Graham Nigel Maw

David James Rawson

Anthony Wood

John Paul Mathias

Stephen Derek A Street

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-23

Filing date

1999-10-19

Publication date

2003-10-15

1998-10-23 Priority claimed from GBGB9823101.2A external-priority patent/GB9823101D0/en

1998-10-23 Priority claimed from GBGB9823102.0A external-priority patent/GB9823102D0/en

1999-10-19 Application filed by Pfizer filed Critical Pfizer

2003-10-15 Application granted granted Critical

2003-10-15 Publication of ATE250063T1 publication Critical patent/ATE250063T1/de

Links

229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title 1
239000002590 phosphodiesterase V inhibitor Substances 0.000 title 1
DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical compound N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 title 1
230000001568 sexual effect Effects 0.000 title 1
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 2
101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 abstract 1
101150098694 PDE5A gene Proteins 0.000 abstract 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000009109 curative therapy Methods 0.000 abstract 1
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT99970992T 1998-10-23 1999-10-19 Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen ATE250063T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9823101.2A GB9823101D0 (en)	1998-10-23	1998-10-23	Pharmaceutically active compounds
GBGB9823102.0A GB9823102D0 (en)	1998-10-23	1998-10-23	Pharmaceutically active compounds
PCT/IB1999/001706 WO2000024745A1 (en)	1998-10-23	1999-10-19	PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION

Publications (1)

Publication Number	Publication Date
ATE250063T1 true ATE250063T1 (de)	2003-10-15

Family

ID=26314550

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99970992T ATE250063T1 (de)	1998-10-23	1999-10-19	Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen

Country Status (11)

Country	Link
EP (1)	EP1123296B1 (de)
JP (1)	JP2002528456A (de)
AT (1)	ATE250063T1 (de)
AU (1)	AU5995699A (de)
BR (1)	BR9915532A (de)
CA (1)	CA2347950C (de)
DE (1)	DE69911448T2 (de)
DK (1)	DK1123296T3 (de)
ES (1)	ES2205945T3 (de)
PT (1)	PT1123296E (de)
WO (1)	WO2000024745A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000035434A2 (en) *	1998-12-14	2000-06-22	Cellegy Pharmaceuticals, Inc.	Compositions and methods for the treatment of anorectal disorders
US7235625B2 (en)	1999-06-29	2007-06-26	Palatin Technologies, Inc.	Multiple agent therapy for sexual dysfunction
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
EP1222190A1 (de)	1999-10-11	2002-07-17	Pfizer Limited	2-(2-substituted-5-heterocyclylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-one als phosphodiesterasehemmer
US6503908B1 (en)	1999-10-11	2003-01-07	Pfizer Inc	Pharmaceutically active compounds
IL139073A0 (en) *	1999-10-21	2001-11-25	Pfizer	Treatment of neuropathy
GB0015462D0 (en) *	2000-06-22	2000-08-16	Pfizer Ltd	Novel process for the preparation of pyrazolopyrimidinones
JP2004501154A (ja) *	2000-06-22	2004-01-15	ファイザー・インク	ピラゾロピリミジノン製造のための新規方法
US6730786B2 (en) *	2000-06-22	2004-05-04	Pfizer Inc	Process for the preparation of pyrazolopyrimidinones
WO2002009713A2 (de) *	2000-08-01	2002-02-07	Bayer Aktiengesellschaft	Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
WO2002022127A1 (en) *	2000-09-13	2002-03-21	Isis Innovation Limited	Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
US6548508B2 (en)	2000-10-20	2003-04-15	Pfizer, Inc.	Use of PDE V inhibitors for improved fecundity in mammals
KR100393160B1 (ko) *	2001-06-14	2003-07-31	한국과학기술연구원	신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
ATE478872T1 (de) *	2002-03-28	2010-09-15	Ustav Ex Botan Av Cr V V I I O	Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
FR2842809A1 (fr) *	2002-07-26	2004-01-30	Greenpharma Sas	NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
GB0219961D0 (en)	2002-08-28	2002-10-02	Pfizer Ltd	Oxytocin inhibitors
US7323462B2 (en)	2002-12-10	2008-01-29	Pfizer Inc.	Morpholine dopamine agonists
DE60332387D1 (de)	2002-12-13	2010-06-10	Warner Lambert Co	Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
EA008596B1 (ru)	2003-04-29	2007-06-29	Пфайзер Инк.	5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
CN100374441C (zh)	2003-06-06	2008-03-12	天津倍方科技发展有限公司	二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
JP2006219373A (ja) *	2003-06-13	2006-08-24	Daiichi Asubio Pharma Co Ltd	Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
US7291640B2 (en)	2003-09-22	2007-11-06	Pfizer Inc.	Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en)	2003-11-24	2009-08-11	Pfizer Inc	Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327319D0 (en) *	2003-11-24	2003-12-24	Pfizer Ltd	Novel pharmaceuticals
DK1742950T3 (da)	2004-04-07	2009-03-16	Pfizer Ltd	Pyrazolo-[4,3-D]-pyrimidiner
WO2006085685A1 (ja) *	2005-02-09	2006-08-17	Takeda Pharmaceutical Company Limited	ピラゾール化合物
ES2313626T3 (es)	2005-03-21	2009-03-01	Pfizer Limited	Derivados de triazol sustituidos como antagonistas de oxitocina.
CA2608018C (en)	2005-05-12	2010-07-13	Pfizer Inc.	Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
NL2000291C2 (nl)	2005-11-10	2009-02-17	Pfizer Prod Inc	1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
MX2010006227A (es)	2010-06-07	2011-12-14	World Trade Imp Exp Wtie Ag	Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
CN102134242B (zh) *	2011-01-21	2013-08-28	浙江大德药业集团有限公司	一种用于治疗阳痿的快速长效的化合物
WO2013067309A1 (en)	2011-11-04	2013-05-10	Xion Pharmaceutical Corporation	Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2014060381A1 (de)	2012-10-18	2014-04-24	Bayer Cropscience Ag	Heterocyclische verbindungen als schädlingsbekämpfungsmittel
CN104884449A (zh)	2012-10-31	2015-09-02	拜尔农作物科学股份公司	作为害虫防治剂的新的杂环化合物
CA2934391A1 (en) *	2013-12-20	2015-06-25	Bayer Pharma Aktiengesellschaft	Glucose transport inhibitors
US11590209B2 (en)	2020-01-21	2023-02-28	Palatin Technologies, Inc.	Use of bremelanotide in patients with controlled hypertension
JP2025513455A (ja)	2022-04-22	2025-04-24	バーテックスファーマシューティカルズインコーポレイテッド	疼痛の治療のためのヘテロアリール化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9013750D0 (en) *	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents

1999
- 1999-10-19 DE DE69911448T patent/DE69911448T2/de not_active Expired - Fee Related
- 1999-10-19 AU AU59956/99A patent/AU5995699A/en not_active Abandoned
- 1999-10-19 PT PT99970992T patent/PT1123296E/pt unknown
- 1999-10-19 AT AT99970992T patent/ATE250063T1/de not_active IP Right Cessation
- 1999-10-19 WO PCT/IB1999/001706 patent/WO2000024745A1/en not_active Ceased
- 1999-10-19 ES ES99970992T patent/ES2205945T3/es not_active Expired - Lifetime
- 1999-10-19 JP JP2000578315A patent/JP2002528456A/ja active Pending
- 1999-10-19 EP EP99970992A patent/EP1123296B1/de not_active Expired - Lifetime
- 1999-10-19 DK DK99970992T patent/DK1123296T3/da active
- 1999-10-19 BR BR9915532-0A patent/BR9915532A/pt not_active IP Right Cessation
- 1999-10-19 CA CA002347950A patent/CA2347950C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU5995699A (en)	2000-05-15
EP1123296B1 (de)	2003-09-17
PT1123296E (pt)	2003-12-31
DE69911448T2 (de)	2004-04-08
ES2205945T3 (es)	2004-05-01
JP2002528456A (ja)	2002-09-03
DK1123296T3 (da)	2003-12-08
WO2000024745A1 (en)	2000-05-04
DE69911448D1 (de)	2003-10-23
CA2347950A1 (en)	2000-05-04
EP1123296A1 (de)	2001-08-16
CA2347950C (en)	2005-05-03
BR9915532A (pt)	2001-08-14

Legal Events

Date

Code

Title

Description

2004-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1123296

Country of ref document: EP

2007-07-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69911448D1 (de)	2003-10-23	Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
ATE298753T1 (de)	2005-07-15	Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung der sexuellen dysfunktion
ATE283856T1 (de)	2004-12-15	Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren
CA2287552A1 (en)	2000-04-23	Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
BR0004779A (pt)	2001-05-29	Compostos farmaceuticamente ativos
AP2002002455A0 (en)	2002-06-30	5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
BR0212924A (pt)	2005-01-04	Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma
CA2322900A1 (en)	2001-04-11	2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors
ATE247117T1 (de)	2003-08-15	Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
TNSN03144A1 (en)	2005-12-23	Pyrrolopyrimidines as protein kinase inhibitors
DE60204760D1 (de)	2005-07-28	Pyrazolo[4,3-d]pyrimidinon-verbindungen als cgmp pde-inhibitoren
AP2003002929A0 (en)	2003-12-31	Pyrrolopyrimidines as protein kinase inhibitors
IL149586A0 (en)	2002-11-10	Pyrimidine derivatives as selective inhibitors of cox-2
SE9904129D0 (sv)	1999-11-15	Novel compounds
ATE389655T1 (de)	2008-04-15	Pyrimidinderivate
WO2002079203A8 (en)	2002-11-21	Imidazo-triazine derivatives as pde 5 inhibitors
DE60226970D1 (de)	2008-07-17	Pyrazinoä1',2':1,6ü-pyridoä3,4-bü indole-1,4-dionderivate
EP1241170A3 (de)	2003-03-12	Pyrazolopyrimidinderivate
TNSN06403A1 (en)	2008-02-22	3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
AP2002002462A0 (en)	2002-06-30	Pharmaceutically active compounds.
ATE296631T1 (de)	2005-06-15	Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation
TR200003877T2 (tr)	2001-06-21	İnsan CD23 üretiminin ve TNF salınmasının ihhibitörleri olan hiydroxamic acid türevleri